- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL's HDI 3000 takes center stage
Ultrasound vendor ATL will usethe RSNA meeting to build on the momentum generated by the Octoberlaunch of HDI 3000, the company's new premium scanner (SCAN 10/26/94).HDI 3000 represents the fourth generation of ATL's all-digitalultrasound technology,
Ultrasound vendor ATL will usethe RSNA meeting to build on the momentum generated by the Octoberlaunch of HDI 3000, the company's new premium scanner (SCAN 10/26/94).HDI 3000 represents the fourth generation of ATL's all-digitalultrasound technology, according to president David Perozek.
In designing HDI 3000, ATL, of Bothell, WA, strove to developa system with improved performance in a more compact, easy-to-usepackage, Perozek said. The scanner weighs 380 pounds and featuresspecially designed wheels as well as a new suspension system tomake it easier to move.
ATL has improved the scanner's image quality over previousmodels by developing a new generation of application-specificintegrated circuits (ASICs), as well as a new software architecture.The system is a 128-channel scanner, like ATL's Ultramark 9 HDIsystem, which will remain in the company's product line.
In addition to HDI, ATL will showcase its Access ultrasoundimage management system, which was cleared by the Food and DrugAdministration this year (SCAN 8/31/94). Access is a PC-basedsystem running on IBM's OS/2 operating system. ATL will show threeworkstations for use with Access, which is DICOM 3.0-compatiblethroughout the system, Perozek said.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
